Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
Become a Member | Sign in
Home>Terms & Conditions
  Terms & Conditions

Press Releases & Product Announcements

Please send all press releases and product announcements to Wherever possible, press releases should be emailed as a Microsoft Word attachment or embedded in the email itself. Images should be sent as separate attachments. Where possible please insert the name(s) of the community(ies) that you wish the press release to be published on into the subject line of the email.

For a full list of all Technology Networks’ communities please click here

Submitting Application Notes

By submitting your application notes to us for online publication you are agreeing to the Terms and Conditions for the application notes section of Technology Networks' communities and, confirming that you have the required copyright to submit these application notes.

Application notes should be submitted to preferably as a PDF, if not as a Microsoft Publisher or PowerPoint file. A 40 - 70 word summary must be sent with each application note submitted.

The name(s) of the website(s) that you wish the application note to be published on should be entered into the subject line of the email. For a full list of all Technology Networks’ communities please click here

Before submitting an application note for online publication please read the terms and conditions below.

Submitting a Poster

Posters submitted by academics and from not-for-profit organizations will be published free of charge. For commercial companies there will be an administration charge of $200 for each poster published. Please contact Kelly Giles for more information.

By submitting your poster to us for online publication you are agreeing to the Terms and Conditions for the Posters section of Technology Networks' communities and confirming that you have the required copyright to submit these posters.

Posters should be submitted using the online submission form which is located within the posters section of each website, (click “submit poster” link). The poster needs to be submitted as a PDF or Microsoft PowerPoint file. A 40 – 70 word summary must be submitted along with the poster.

If you have any problems with you submission, please contact, stating the name of the website you wish to publish your poster on in the subject line.

Before submitting a poster for online publication please read the terms and conditions below.


1. Services / Consideration.
Technology Networks Ltd. ('TechNet') shall develop an electronic version of the printed Application Note or Poster that has been created from the files provided by you (the 'Author'). In consideration of TechNet's development, archiving and retrieval of the Author's Application note, Author shall: (a) grant the license stated in Section 3.

2. Copyright Ownership.
As between TechNet and Author, Author shall be the owner of all copyrights in and to the content contained in the Print Application Note or poster and the online Application Note or Poster.

3. Copyright License.
In order for TechNet to electronically archive, display and distribute the Application Note or Poster, Author hereby grants to TechNet an irrevocable, perpetual license to maintain, store, cache, copy and distribute (in any current or future media) the Application Note or Poster (the 'License Grant'). The License Grant includes TechNet's right to include the Application Note or Poster in its current and future database or databases as well as to distribute the Application Note or Poster electronically to third parties through any one or more websites operated by or on behalf of TechNet.

4.Representations and Warranties.
Author hereby represents and warrants to TechNet that: (i) Author is the owner or authorized licensee of all right, title and interest (including all copyrights and other intellectual property rights) in and to all content that appears on the Application Note or Poster; (ii) all content that appears in the Application Note or Poster is the Author's original work and contains no libelous or unlawful statements, does not infringe on the rights or privacy of others or contain material or instructions that might cause harm or injury, (iii) Author's execution and performance of this Agreement does not and shall not constitute a breach of, or otherwise violate, any written or verbal understanding or agreement between Author and any third party; and (iv) TechNet's use of the files provided by the Author to create the Application Note or Poster, as well as TechNet's exercise of its rights pursuant to the License Grant, shall not infringe or violate the copyrights, or other intellectual property rights, of any third party.

(a) This Agreement shall be construed and enforced in accordance with the laws of the United Kingdom. Each party hereby consents to the exclusive jurisdiction and venue of any court located in the United Kingdom with respect to any claim or controversy arising out of or related to this Agreement.

(b) This Agreement: (i) shall benefit and bind each party and their successors and assigns; (ii) contains the entire understanding and agreement of the parties; and it incorporates or supersedes all other written or verbal agreements and understandings with respect to the subject matter; and (iii) may be amended or modified only in writing signed by both parties and referring specifically to the Agreement.

Scientific News
Lucentis Effective for Proliferative Diabetic Retinopathy
NIH-funded clinical trial marks first major advance in therapy in 40 years.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.
First Therapy Appearing to Reverse Decline in Parkinson’s
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC).
Gene Therapy Staves Off Blindness from Retinitis Pigmentosa in Canine Model
NIH-funded study suggests therapeutic window may extend to later-stage disease.
Treatment for Rare Bleeding Disorder is Effective
Researchers in Manchester have demonstrated for the first time the relative safety and effectiveness of treatment, eltrombopag, in children with persistent or chronic immune thrombocytopenia (ITP), as part of an international duo of studies.
HIV Vaccine Human Trials Begin
Baltimore-based Institute has begun enrolling volunteers for initial phase 1 clinical trials.
New Therapy Reduces Symptoms of Inherited Enzyme Deficiency
A phase three clinical trial of a new enzyme replacement medication, sebelipase alfa, showed a reduction in multiple disease-related symptoms in children and adults with lysosomal acid lipase deficiency, an inherited enzyme deficiency that can result in scarring of the liver and high cholesterol.
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
Scroll Up
Scroll Down

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos